Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 13,075 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Melanoma (Skin)
Interventions: dasatinib; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 153
States / cities: Little Rock, Arkansas • Stanford, California • Fort Lauderdale, Florida + 106 more

Conditions: HIV Infections
Interventions: HIV screening strategies; Other
Lead sponsor: Westat; Other
Eligibility: 14 Years to 24 Years
Enrollment: 84,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: Dexmedetomidine, Sedation
Interventions: Intranasal dexmedetomidine; Drug
Lead sponsor: Columbia University; Other
Eligibility: 2 Months to 17 Years
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: San Jose, California • Atlanta, Georgia • Springfield, Illinois + 5 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Nevirapine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Beverly Hills, California • San Francisco, California • Denver, Colorado + 7 more

Conditions: Major Depressive Disorder
Interventions: AXS-05, Bupropion; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 40
States / cities: Bellflower, California • Lafayette, California • Oceanside, California + 34 more

Conditions: Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
Interventions: Cytology Specimen Collection Procedure; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 2,545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 175
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more

Conditions: Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Heart-Lung Transplantation
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 11 Years to 18 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Alcohol Misuse, Tobacco Use, Mindfulness, Stress
Interventions: mindfulness-based intervention, comparison intervention; Behavioral
Lead sponsor: Georgia State University; Other
Eligibility: 18 Years to 24 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IIIA Ovarian Cancer 2014, FIGO Stage IIIA1 Ovarian Cancer, FIGO Stage IIIA2 Ovarian Cancer, FIGO Stage IIIB Ovarian Cancer 2014, FIGO Stage IIIC Ovarian Cancer 2014, FIGO Stage IVA Ovarian Cancer 2014, FIGO Stage IVB Ovarian Cancer 2014, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions: Carboplatin, Paclitaxel, Ruxolitinib Phosphate, Therapeutic Conventional Surgery; Drug · Procedure
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 110
States / cities: Goodyear, Arizona • Auburn, California • Los Angeles, California + 87 more

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: E/C/F/TAF, E/C/F/TAF (Low Dose); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 5
States / cities: Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more

Conditions: Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm, Brain Aneurysm
Interventions: Flow diversion; Device
Lead sponsor: phenox Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 21 more

Conditions: Extensive Stage Lung Small Cell Carcinoma
Interventions: Carboplatin, Cediranib, Cediranib Maleate, Cisplatin, Etoposide, Olaparib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Los Angeles, California • Pasadena, California • Jacksonville, Florida + 15 more

Conditions: Crohn's Disease
Interventions: GED-0301, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 12 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: San Diego, California • Atlanta, Georgia • Indianapolis, Indiana + 18 more

Conditions: Chronic Thromboembolic Pulmonary Hypertension
Interventions: Macitentan, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 20 more

Conditions: Plaque Psoriasis
Interventions: M518101, placebo, Dovonex; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 32
States / cities: Birmingham, Alabama • Mobile, Alabama • Fresno, California + 28 more

Conditions: Renal Cell Carcinoma
Interventions: Cabozantinib, Nivolumab, Ipilimumab, Cabozantinib-matched placebo; Drug · Biological
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 30
States / cities: La Jolla, California • Orange, California • Boca Raton, Florida + 23 more

Conditions: Raynaud's Disease, Peripheral Vascular Disease
Interventions: PF-00489791; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Redwood City, California • Farmington, Connecticut • Washington D.C., District of Columbia + 19 more

Conditions: Lupus Nephritis
Interventions: Micro-learning content, Health360x app, Culturally congruent coaching; Behavioral
Lead sponsor: Morehouse School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder
Interventions: Agomelatine (AGO178C), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 43
States / cities: Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more

Conditions: Pain Management
Interventions: MK-6916, Hydrocodone/acetaminophen (HB/APAP), MK-6916 Placebo, Rescue Medication; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions: Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo; Procedure · Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 5 Minutes to 10 Days
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more

Conditions: COPD
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Infant, Newborn, Hypoxia-Ischemia, Brain
Interventions: Induced hypothermia, Control; Device
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 6 Hours
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Pervasive Development Disorders
Interventions: placebo, extended-release guanfacine; Other · Drug
Lead sponsor: Yale University; Other
Eligibility: 5 Years to 14 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more

Search by objective public record fields.

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Screen2Prevent (S2P)

Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Quality of Life in Pediatric Transplant Recipients

A Mindfulness-based Intervention for Sexual Assault Survivors

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

PF-00489791 For The Treatment Of Raynaud's

Wellness & Workforce Solution for Lupus/Lupus Nephritis

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

Study on COPD Corticosteroid-induced Hyperglycemia on Clinical Outcome in Patients With COPD

Whole-Body Cooling for Birth Asphyxia in Term Infants

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder